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ABSTRACT  
Oxygen activation in all heme enzymes requires the formation of high oxidation states of 
iron, usually referred to as ferryl heme. There are two known intermediates: Compound I and 
Compound II. The nature of the ferryl heme – and whether it is an FeIV=O or FeIV-OH 
species – is important for controlling reactivity across groups of heme enzymes. The most 
recent evidence for Compound I indicates that the ferryl heme is an unprotonated FeIV=O 
species. For Compound II, the nature of the ferryl heme is not unambiguously established. 
Here, we report 1.06 Å and 1.50 Å crystal structures for Compound II intermediates in 
cytochrome c peroxidase (CcP) and ascorbate peroxidase (APX), collected using the X-ray 
free electron laser at SACLA. The structures reveal differences between the two peroxidases. 
The iron-oxygen bond length in CcP (1.76 Å) is notably shorter than in APX (1.87 Å). The 
results indicate that the ferryl species is finely tuned across Compound I and Compound II 
species in closely related peroxidase enzymes. We propose that this fine-tuning is linked to 
the functional need for proton delivery to the heme.  
 
INTRODUCTION 
A large number of heme enzymes use ferryl heme during catalysis. Ferryl heme refers 
broadly to a highly oxidized form of the heme in which the iron is in an oxidation state that is 
either one equivalent (FeIV, known as Compound II) or two equivalents (formally FeV, known 
as Compound I) above the resting oxidation state (FeIII). The second oxidizing equivalent in 
Compound I resides on the porphyrin ring or, in some cases, on a protein radical[1].  
 
These Compound I and Compound II species were identified in the late 1930s[2] and were 
later given their names[3]. Because these intermediates are used in such a wide range of 
catalytic enzymes, they continue to attract attention these many years later[4]. The chemical 
nature of the ferryl species has therefore been a matter of intense interest. The discussion has 
often focussed on whether the ferryl species is best formulated as an unprotonated FeIV=O or 
a protonated FeIV-OH species. This matters because the protonation state controls the 
reactivity. The majority of the early spectroscopy on these intermediates was carried out on 
one of the more experimentally amenable peroxidases (usually horseradish peroxidase or 
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cytochrome c peroxidase), or on myoglobin, each of which contain a histidine as proximal 
ligand. Most, but not all, of this information favoured an unprotonated FeIV=O species for 
Compound I[5]. But the difficulty of the experiments on such unstable species, coupled with 
the problems associated with generating them in quantitative yields and sometimes in high 
concentrations, meant that the literature was inconclusive.  
 
From about 2000 onwards, the field moved away from spectroscopy and X-ray 
crystallographic work became feasible instead. Since protons are not normally visible at the 
resolutions typically observed for protein crystal structures, the question instead became 
focussed on the iron-oxygen bond length which was taken as an indirect reporter of bond 
order (single or double). Protonation state (FeIV=O or FeIV-OH) is thus inferred from the 
bond length measured in the structure. But the picture did not clarify when X-ray structures 
of ferryl species emerged, because the structures revealed bond lengths that were longer than 
would be expected for a pure FeIV=O species and were thus out-of-line with most of the 
earlier spectroscopy. Photoreduction of metal ions in the synchrotron beam is now known to 
be an issue that affects oxidation states of metal ions in metalloprotein structures[6], including 
those for the early Compound I crystal structures (reviewed in [1b, 7]). X-ray free electron 
lasers (XFEL) avoid this problem because it becomes possible to collect the diffraction data 
within femtosecond timescales, which allows data collection before the X-ray induced 
photoreduction/radiation damage take place[8].  
 
In this work, we present XFEL structures of Compound II in two different peroxidases – 
cytochrome c peroxidase and ascorbate peroxidase. The data indicate differences in the 
nature of the ferryl species between the Compound II intermediates in the two enzyme 
intermediates. The functional implications of this finding, in terms of proton delivery to the 
heme, are discussed.  
 
RESULTS  
Compound II in CcP. Of all the heme enzymes, CcP provides a very convenient framework 
for examination of ferryl reactivity. But while formation of Compound I in CcP is 
straightforward (because Compound I is a stable intermediate), formation of Compound II 
with high purity is not. This is in part because the UV-visible spectra of Compounds I and II 
are very similar[9] which makes it difficult to differentiate the two. And, it means that the 
most convenient and commonly used method for Compound II formation – namely by decay 
of Compound I (e.g. [10] [11]) – cannot be used for CcP. 
 
We thus developed an anaerobic procedure for direct formation of Compound II in CcP (see 
Experimental). Under anaerobic conditions, reaction of ferric CcP with dithionite led to 
formation of a stable ferrous species (λmax = 440, 558, 590sh nm, Fig. 1A). Further reaction 
with H2O2 yielded a species with wavelength maxima (λmax = 420, 530, 560 nm, Fig. 1B) 
similar to those reported for Compound II of CcP[9]. EPR was used to verify Compound II 
formation; Compound I is EPR-active and Compound II is not. Absorption spectra of EPR 
samples were recorded prior to flash freezing in EPR tubes, to confirm the correct spectral 
features (Fig. 2A).  The EPR signals characteristic of high-spin ferric CcP (g⊥ = 6 and g = 
1.99) disappear in the ferrous and Compound II spectra, both of which are EPR-silent, Fig. 
2B. No new resonances are observed in the EPR-silent spectrum of Compound II, consistent 
with the presence of a ferryl heme (S = 1 species).  
 
Single crystal spectrophotometry at 100 K on crystals of CcP that had been reduced with 
dithionite under anaerobic conditions, followed by anaerobic reaction with H2O2 (see 
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Experimental), showed absorption peaks for Compound II (λmax = 530, 560 nm, Fig. 3A) that 
reproduce those in solution above. Single crystal EPR spectra, Fig. 3B, also show formation 
of an EPR-silent species (i.e Compound II). 
 
The X-ray free electron laser (XFEL) structure of Compound II of CcP, prepared in crystals 
as above, was obtained at 1.06 Å resolution. Data collection and refinement statistics are 
given in Table S1. An electron density map in the region of the heme pocket is shown in Fig. 
4A. At this resolution it becomes possible to see the peaks in electron density associated with 
hydrogen atoms, and this difference density is shown in Fig. 5A. Note that although electron 
density at the positions of hydrogen atoms in Fig. 5A confirms their presence, absence of 
observed density cannot be taken as unequivocal proof of absence of a hydrogen at that point. 
Nonetheless, in this structure the Nε atom of His52 shows no density for a hydrogen atom 
and the imidazole is therefore more likely to be neutral (not protonated). This is in contrast to 
the neutron structure of Compound I in CcP[12], in which the Nε atom of His52 is carrying a 
proton. This change in protonation is consistent with a role for the distal histidine residue in 
regulating proton delivery to the ferryl species. Trp51 retains its hydrogen on Nε, and the 
guanidinium group of Arg48 is flat with density for all the hydrogens expected when 
positively charged, the state observed in the neutron structure of Compound I[12].  
 
The Fe-O bond length extracted from this XFEL structure of CcP Compound II is 1.76 Å. 
The complete models were refined with SHELXL[13] allowing estimation of individual 
atomic positional uncertainties (ESU). The ESU of the iron and oxygen positions are 0.004 
and 0.02 Å respectively. There are several key points to note when comparing with 
Compound I. First, the hydrogen bond patterns to the ferryl are the same in CcP Compound I 
and II (i.e. hydrogen bonds to the Nε atoms on Arg48 and the Nε proton of Trp 51, Figure 
5B) and do not allow space for a OH species bonded to the ferryl. These hydrogen bonds to 
Arg48 and Trp51 appear to be “locked in”, as the same hydrogen bonding pattern is observed 
in the X-ray structure of CcP Compound I[10] and in the neutron structure[12], Fig. 5B. Since 
the neutron structure of Compound I in CcP conclusively identifies a FeIV=O species (from 
the absence of nuclear density for a OH species), then we therefore interpret this ferryl 
species in Compound II of CcP as also being unprotonated (i.e. a FeIV=O species). This 
would be consistent with the fact that the uv-visible spectra of Compounds I and II are 
indistinguishable. That said, the bond length of 1.76 Å in this CcP Compound II structure is 
measurably and (within error) longer than that for CcP Compound I (1.63 Å[10, 12]). Since this 
bond lengthening does not affect the hydrogen bonding patterns on the distal side, we take 
this to mean that the bond length of an unprotonated FeIV=O species can be flexible within a 
single enzyme (and therefore that factors other than these distal hydrogen bonds affect bond 
length). We elaborate these ideas in the Discussion.  
 
Compound II in APX. In a set of parallel experiments, single crystals of Compound II in APX 
were prepared by reaction with m-chloroperbenzoic acid, as previously[14]. Accordingly, an 
X-ray free electron laser structure of Compound II of APX was also obtained at 1.50 Å 
resolution (see Table S1). In this structure (unlike CcP above), the resolution is not high 
enough to see hydrogen atoms. An electron density map of the distal heme region is shown in 
Fig. 4B. In this structure, the iron-oxygen bond length is 1.87 Å, and the ESU of the iron and 
oxygen positions are 0.014 and 0.083 Å respectively. This bond length in Compound II in 
APX is longer than that found in CcP and agrees with previous X-ray[10] and neutron[14] 
structures. While bond lengths are determined from much lower resolution data in neutron 
experiments, the X-ray[10], neutron[14] and XFEL (this work) data are, nevertheless, in 
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agreement with one another. Positive nuclear density has identified an FeIV-OH species for 
Compound II in APX[14], which is in agreement with the longer bond.  
The electron density for the side-chain of Arg38 (equivalent to Arg48 in CcP) is weak, 
occupying two different positions, Fig. 5C. In one location (the “in” position (14)) the Nε 
atom of Arg38 is hydrogen bonded to the ferryl heme, exactly as in CcP above. In the other 
position (“out”), Arg38 moves away from the ferryl group, and exchanges with a water 
molecule (Fig. 5C). This movement of the distal Arg residue is not evident in CcP. The 
functional implications of these differences between APX and CcP are discussed below.  
 
DISCUSSION 
A variety of methods have been used to examine the nature of ferryl heme (FeIV=O versus 
FeIV-OH). These include resonance Raman and Mossbauer spectroscopies, EXAFS, and X-
ray crystallography. Many of these studies have been carried out on peroxidase enzymes, 
because their ferryl intermediates are well known and are more stable than the corresponding 
species in other enzymes (such as P450s) which use the same intermediates. It is worth 
remembering that none of the spectroscopic methods, nor X-ray diffraction (unless at 
resolutions of ca. 1 Å, where the electrons of hydrogen atoms may be seen), can directly 
identify the locations of hydrogens so the positions of protons are inferred. To add to the 
technical difficulty, X-ray induced photoreduction, particularly of positively charged centres 
such as metal ions is acknowledged to occur during crystal structure determination[15]. 
Photoreduction can also be an issue in X-ray absorption spectroscopy studies[16] and 
resonance Raman studies[17].  
 
One method where hydrogens (usually as deuterons) are observed directly is in neutron 
diffraction, and in a neutron experiment photoreduction does not occur because the neutrons 
are scattered by nuclei and not (as in an X-ray experiment) by electrons. We have previously 
used neutron diffraction to examine the ferryl species in Compound I of cytochrome c 
peroxidase. The nuclear density maps demonstrate that Compound I in CcP is an FeIV=O 
species and is not protonated[12]. These conclusions on Compound I agree with measurements 
of bond lengths in multi-crystal X-ray[10, 18] and XFEL[19] studies on CcP, and with kinetic 
and spectroscopic work on Compound I in two proximal thiolate-ligated heme enzymes 
(cytochrome P450[20] and the fungal peroxygenase from A. aegerita[21]). A consensus on 
Compound I therefore seems to be emerging.  
 
The protonation state of the ferryl heme in Compound II is less well clarified. Positive 
nuclear density in the neutron crystal structure of Compound II of ascorbate peroxidase 
(APX)[14] definitely identifies a OH ligand (FeIV-OH), although recent spectroscopic 
information is in favour of an unprotonated species[22]. One philosophy[11] is that histidine-
ligated heme systems are constitutionally unable to form a FeIV-OH species, because they 
lack a proximal thiolate (electron donating) ligand which is considered a key requirement. On 
the other hand, heme enzymes without a thiolate ligand can form FeIV-OH[23], so the presence 
of a thiolate ligand is not essential for FeIV-OH formation in all cases. 
 
For Compound II, more information is needed to unpick these key biological questions. 
XFEL provides an alternative approach to both traditional X-ray crystallography and to 
neutron crystallography techniques, in the sense that structures can be generated on 
femtosecond timecales that avoid X-ray induced photoreduction or radiation damage. The 
XFEL structure of Compound II of CcP, resolved to 1.06 Å, shows a Fe-O bond length of 
1.76 Å. This bond length is longer than that obtained using a multi-crystal X-ray method for 
Compound I of CcP (1.63 Å, determined at 1.67 Å resolution and with an ESU of the iron 
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and oxygen atom positions of 0.017 and 0.066 Å respectively[10]). The corresponding XFEL 
structure of Compound II in APX, resolved at 1.50 Å, shows a Fe-O distance of 1.87 Å which 
is almost identical to that obtained from multi-crystal X-ray (1.84 Å[10]) and neutron 
structures (1.88 Å[14], as shown in Fig. S3). 
 
Comparison with other ferryl species 
Empirically-determined distances for Fe-O bond lengths are quite reasonably often used as a 
binary determinant of bond order (single or double bond) and, by implication, of protonation 
state in ferryl complexes. But the comparison of the closely related CcP and APX enzymes 
above and the analysis below indicates that the situation might be considerably more 
complicated. Comparison of CcP and APX shows evident flexibility (or certainly variability) 
in the bond lengths of ferryl species. The most reliable bond lengths for Compound I in 
proteins have typically been within a range of ca 1.63 – 1.73 Å (Table S2) and are assigned 
as arising from FeIV=O species. For FeIV-OH species, the bond is expected to be longer than 
for FeIV=O, but by how much? The FeIV=O bond length itself can vary, as we show above for 
Compounds I and II in CcP and also in Table S1, so there may be movement in these protein 
bond lengths under certain conditions. This would mean that there could be overlap between 
the expected bond lengths for FeIV=O, FeIV-OH and even FeIII-OH species, making them hard 
to differentiate by virtue of bond length alone.  
 
There is evidence to support such flexibility in other enzymes. Consider for example the 
FeIV-OH bond length for chloroperoxidase Compound II (1.82 Å[24]) which is very close to 
the FeIII-OH bond length in myoglobin (1.86 Å[25]). Consider also that in Compound II of H. 
pylori catalase[23a] the Fe-O bond length (1.78 Å) has been interpreted[23a] as a FeIV-OH 
species (in agreement with P. mirabilis catalase[23b]), but is arguably is within range of an 
unprotonated (FeIV=O) species (e.g. 1.73 Å[18]). That the bond lengths for some Compound II 
intermediates are in a range that overlap with FeIII-OH, and that bond lengths for FeIV=O and 
FeIV-OH species can be closely merged together in different proteins, blurs the boundaries 
between individual species. We note also a recent XFEL analysis[26] of a stable Compound I 
species in a dye-decolorising peroxidase (DyP), which shows the expected short Fe-O bond 
length in one monomer of the crystal (1.65 Å), but much longer bonds (1.70 – 1.89 Å) in five 
others of the asymmetric unit at both room temperature (from XFEL data) and at 100 K (from 
synchrotron data).  
 
An examination of structures of inorganic ferryl complexes further elaborates the above 
analysis. A range of bond lengths is observed for genuine FeIV=O species (1.62 – 1.70 Å, Fig. 
6B); these are notably shorter than the equivalent FeIII–OH species,  Fig. 6A. The range of 
Fe-O bond lengths for Compound I protein species (1.63 – 1.73 Å) is wider, but in reasonable 
agreement of those for the inorganic complexes (compare Fig. 6B,C). Regardless of whether 
they are assigned as FeIV=O or FeIV-OH species, the bond lengths for Compounds II are all 
longer (1.76 Å– 1.88 Å, Fig. 6D). The only structure for an inorganic FeIV-OH species 
reports a similar bond length of 1.86 Å[27], highlighted in Fig. 6B, but the both the inorganic 
and protein FeIV-OH species are in a region that overlaps with the numerous FeIII-OH 
structures, Fig. 6A.  
 
Functional implications  
Taking all of this information together, while considering at the same time the enzymatic 
requirements to do with the O-O bond cleavage event, it appears that there is a range of bond 
lengths that any particular species (FeIV=O or FeIV-OH) might populate. Flexing of the bond 
and the bonding parameters might better reflect the range of dynamic motions that occur 
 6 
around the ferryl heme in different heme enzymes during catalytic turnover. This could be 
moderated by variables such as axial ligand, local charge, temperature,  secondary 
coordination sphere and in particular hydrogen bonding[28] as discussed below.  
 
The data from the two XFEL structures of Compound II highlights differences in hydrogen 
bonding in the active site of these two closely related heme enzymes. In Compound II of 
APX, the distal Arg38 residue is mobile and is observed in two conformations in the 
structure. This is not observed in CcP. Movement of Arg38 changes the hydrogen bonding 
patterns in the active site, as shown in Fig. 5C. Arg38 is involved in proton delivery from the 
substrate (ascorbate) to the heme group during catalysis[29]. And, neutron crystallography[30] 
supports a role for Arg38 in proton delivery because Arg 38 is neutral (having lost a proton in 
the complex) in the APX-ascorbate complex. In one of the two locations for Arg38 (the “out” 
position, Fig. 5C (left)), there is a water molecule hydrogen bonded to the ferryl oxygen. In 
the other “in” position (Fig. 5C (right)), Arg38 hydrogen bonds to the ferryl oxygen in the 
same way as in CcP (Figure 5B); in this conformation Arg38 would need to be a hydrogen 
acceptor to a proton on the ferryl oxygen, and this can only be achieved if Arg38 is in the 
neutral state (as seen in[30]). This highly dynamic hydrogen bonding arrangement in APX is 
presumably linked to the functional need for proton transfer from the substrate (ascorbate) 
and mediated by movement of Arg38 - it involves two proton donors (water and Arg38) in 
two conformations. This could account for the longer Fe-O bond in Compound II of APX 
compared to CcP, and would provide a mechanism to facilitate movement of protons in an 
out of the active site. Hydrogen bonding to the distal histidine residue (or in other words 
whether the distal histidine is protonated or not) might also be important in regulating the 
bonding parameters[31]. There is strong evidence from this study and our previous work for 
different protonation states of the distal histidine[12, 14, 30], which will change the hydrogen 
bonding patterns. We note also that pH-dependent changes in resonance Raman stretching 
frequencies for Compound II of both horseradish peroxidase[32] and myoglobin[25] are 
generally considered to arise from changes in hydrogen bonding to the ferryl. 
 
By comparison, as we have shown above, no such flexibility in hydrogen bonding to the 
distal Arg is observed in CcP, as the active site hydrogen bond structure is “locked” in a fixed 
arrangement that does not change between Compounds I and II. That the electron transfer 
delivery pathway between ascorbate and the ferryl heme in APX (through Arg38 and the 
heme propionate[33]) is not replicated in CcP would be consistent with the different patterns 
of hydrogen bonding that we observe. In CcP, the electrons are delivered from cytochrome c 
through the proximal side[34], and so shuttling of protons from a substrate (at the heme edge) 
to the ferryl, mediated by the distal Arg, and changes in hydrogen bonding, are not a requiste 
part of the mechanism.  
 
These results demonstrate not only the precise fine-tuning that can exist within structurally 
almost identical heme active sites, but the ways in which this is connected to functional 
differences to do with substrate specificity. This information will feed into de novo design of 
new catalysts, aimed at mimicking heme protein reactivity and selectivity.   
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FIGURE LEGENDS 
Figure 1. Formation of Compound II in CcP monitored by stopped-flow. (A) Formation of 
ferrous CcP – Ferric CcP (6 μM) was mixed with 2-3 equivalents of dithionite and spectra 
monitored over 10 s. The dashed line is the first species observed after mixing and represents 
the ferric enzyme, and the solid line represents the ferrous spectrum which was completely 
formed within 10s of the mixing event. Absorbance values in the visible region have been 
multiplied by a factor of three. Conditions: 10 mM potassium phosphate, 150 mM KCl pH 
6.5, 25.0 °C. This ferrous species was stable for at least 15 minutes at room temperature, after 
which time it decayed back to ferric. (B) Formation of CcP Compound II – In a sequential 
mixing experiment ferric CcP (6 μM) was premixed with a stoichiometric amount of 
dithionite for 10 s (to enable complete formation of ferrous CcP) followed by mixing with 
H2O2 (5 equivalents) and spectral changes monitored over 10 s. The dashed line is the first 
species observed after mixing and represents the ferrous species (at t = 1 ms); this spectrum 
(λmax = 439, 558, 590sh nm) is similar to the spectrum of the ferrous enzyme formed in the 
single mix experiments in (A). The solid line after reaction with H2O2 is assigned as a 
Compound II species (λmax = 420, 530, 560 nm). Over longer timescales (~ 500 s), this 
Compound II species was observed to decay slowly (kobs ≈ 0.004 s-1) back to a ferric-like 
species (Fig. S1).  
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Figure 2. Formation of Compound II in CcP monitored by EPR. (A) Absorption spectra of 
ferric, ferrous and Compound II forms of CcP used for EPR analysis – Ferric CcP (250 µM, 
dotted line) was reacted with 5-10 equivalents of dithionite to produce ferrous CcP (dashed 
line); Compound II (black solid line) was prepared by reaction of ferrous protein with 
10 equivalents of H2O2. All spectra were recorded immediately after mixing and prior to flash 
freezing. Absorbance values in the visible region have been multiplied by a factor of three. 
Conditions: 10 mM potassium phosphate, 150 mM KCl pH 6.5, 25.0 °C. (B) EPR spectra – 9 
GHz EPR spectra of the corresponding solutions from the experiments in (A) of the ferric 
(top spectrum), ferrous (middle spectrum) and Compound II (bottom spectrum) derivatives of 
CcP prepared by reaction of ferrous CcP with 10-equivalents of H2O2 and flash frozen 
immediately after mixing (see Experimental).   
Figure 3. Formation of Compound II of CcP in crystals. (A) Single crystal UV-visible 
spectra (100 K) of crystals of formed by reaction with dithionite (to give ferrous CcP, solid 
line), followed by reaction with 0.2 mM H2O2 (to give Compound II, dashed line). (B) 9 GHz 
EPR spectra of single crystals of CcP. (i) Ferric CcP. (ii) Compound I formed by reaction of a 
ferric crystal with 0.2 mM H2O2. (iii) After storage of the crystal in (ii) for 20 days in liquid 
nitrogen; (iv) Compound II formed by reaction with dithionite and H2O2 as in (A). (v) After 
storage of the sample in (iv) for 20 days in liquid nitrogen; (vi) Background.  
Figure 4. XFEL crystal structures of Compound II. (A) CcP Compound II – Electron density 
of CcP Compound II is shown in blue (contoured at 2.0 σ). The O atom is positioned at 1.76 
Å from the heme iron. Oxygen atoms of water molecules are shown in light blue, and the 
ferryl oxygen is shown in red (to differentiate it from water). (B) APX Compound II – 
Electron density of APX Compound II is shown in blue (contoured at 2.0 σ). The difference 
density calculated by omitting Arg 38 is shown in green (contoured at 3 σ). Note the weak 
density beyond the Cδ of the side chain for Arg 38 (shown at 1.2 σ). Atoms of Arg 38 are 
shown in grey where the atomic positions are unclearly defined. The ferryl O atom is 
positioned at 1.87 Å from the heme iron. Oxygen atoms of water molecules are shown in 
light blue, and the ferryl oxygen is shown in red, as for (A).  
Figure 5. Hydrogen bonding in the active site. (A) Electron density of CcP Compound II is 
shown in blue (contoured at 2.0 σ). The difference density calculated by omitting hydrogens 
are shown in green (contoured at 3 σ). The O atom is positioned at 1.76 Å from the heme 
iron. Water is shown in light blue color. (B) Hydrogen bonding patterns for Compound II in 
CcP. (C) Hydrogen bonding patterns for Compound II in APX showing Arg38 in two 
different locations - the “out” (left, as in Figure 4B above) and “in” (right) positions. Waters 
are shown in light blue, and swap interchangeably as Arg38 moves between the two 
locations. Note that in the ‘out’ position, Arg38 is hydrogen bonded to the water molecule 
through the Nη, and not as previously[14] through the adjacent Nε. The ferryl oxygen is 
shown in red and hydrogen bonds are in dotted lines in all figures.  
Figure 6. Comparison of Fe-O bond lengths obtained for various ferric (A) and ferryl (B) 
inorganic structures in the Cambridge Structure Database, alongside those for Compound I 
and Compound II protein structures (C, D). Photoreduction is not a complicating factor in 
small molecule crystal structures. (A) Plot showing Fe-O bond lengths for complexes of iron 
in the ferric oxidation state in the Cambridge Structure Database. The plot shows only ferric 
structures with hydroxide (OH, highlighted in red circles) or water (H2O, black) as a ligand to 
the iron. Not shown in this plot, are structures for a FeIII=O species (Fe-O = 1.81 Å [35]). The 
majority (all but three) of the FeIII-OH structures in the CSD lie in the range 1.8 – 1.9 Å. (B) 
The equivalent plot for complexes of iron in the ferryl oxidation state, in the Cambridge 
Structure Database. All structures are assigned as FeIV=O species, with the exception one 
structure which is assigned as FeIV-OH (red circle [27]). Exact bonds lengths for each of the 
individual FeIV species are given in the SI. (C) Fe-O bond distances obtained from crystal 
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structures of Compound I (see also Table S2). (D) The same as (C), but for Compound II (see 

































Enzymatic fine-tuning of heme reactivity. Free-electron laser crystal structures of two different 
heme-containing peroxidases – cytochrome c peroxidase and ascorbate peroxidase – show 
differences in the nature of the ferryl species. Precise enzymatic fine-tuning within structurally 
similar heme active sites is implicated.  
 
 
